SUSTAINED DRUG DELIVERY SYSTEM

• US 20120177717A1
• Filed: 02/16/2012
• Published: 07/12/2012
• Est. Priority Date: 08/18/2009
• Status: Active Grant

• Current Assignee: Tohoku University National Universities Corporation
• Original Assignee: Tohoku University National Universities Corporation
• Inventors: ABE, Toshiaki, NAGAI, Nobuhiro, KAJI, Hirokazu, KAWASHIMA, Takeaki, NISHIZAWA, Matsuhiko, NISHIDA, Koji
• Granted Patent: US 8,642,066 B2
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/4808 characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Disclosed is a drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. Specifically disclosed is a sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.

Claims

1. A drug slow-releasing implant, wherein the implant is a PEG capsule having a structure in which a box-shaped PEG internally comprising a therapeutic drug, a collagen impregnated with the therapeutic drug, or a PEG pellet in which the collagen impregnated with the therapeutic drug is embedded is capped with a porous PEG sheet and the internal drug is slowly released through the porous PEG sheet.

2. The drug slow-releasing implant according to claim 1, wherein the implant is a stepwise slow-releasing implant in which the collagen impregnated with the therapeutic drug or the PEG pellet in which the collagen impregnated with the therapeutic drug is embedded is internally comprised in the box-shaped PEG.

3. The drug slow-releasing implant according to claim 1, wherein the therapeutic drug for impregnation is in the form of a solution, powdered particles, or a mixture thereof.

4. The drug slow-releasing implant according to claim 1, wherein the collagen impregnated with the therapeutic drug is in the form of a collagen gel or collagen particles.

5. The drug slow-releasing implant according to claim 1, wherein the PEG pellet in which the collagen impregnated with the therapeutic drug is embedded is prepared by mixing the collagen impregnated with the drug, a photo-curable polyethylene glycol, and a photopolymerization initiator and curing the mixture with UV light.

6. The drug slow-releasing implant according to claim 1, wherein the box-shaped PEG is prepared by mixing a photo-curable polyethylene glycol and a photopolymerization initiator and curing the mixture with UV light.

7. The drug slow-releasing implant according to claim 1, wherein the porous PEG sheet is prepared by mixing a photo-curable polyethylene glycol solution, collagen particles, and a photopolymerization initiator, irradiating the mixture with UV light for curing, and then digesting the collagen particles.

8. The drug slow-releasing implant according to claim 5, wherein the photo-curable polyethylene glycol is selected from the group consisting of polyethylene glycol dimethacrylate (PEGDM), polyethylene glycol methacrylate (PEGMA), and polyethylene glycol diacrylate (PEGDA).

9. The drug slow-releasing implant according to claim 1, wherein the implant is for treating eye disease and implanted in the sclera that is a portion from above the choroid to under the conjunctiva, that is, the subsclera, the inside of the sclera, the episclera, the subconjunctiva, and the suprachoroid.

10. The drug slow-releasing implant according to claim 9, wherein the eye disease is a disease in which multiple factors including a gene and an environmental factor are involved, a retinal blood vessel lesion, or a disease in which inflammation or damage spreads to the choroid/retina/vitreous body.

11. The drug slow-releasing implant according to claim 10, wherein the disease in which multiple factors including a gene and an environmental factor are involved is selected from the group consisting of retinal pigmentary degeneration, age-related macular degeneration, and glaucoma;

the retinal blood vessel lesion is selected from the group consisting of retinal artery occlusion, branch retinal vein occlusion, and diabetic retinopathy; and

the disease in which inflammation or damage spreads to the choroid/retina/vitreous body is uveitis.

12. The drug slow-releasing implant according to claim 1, wherein the therapeutic drug is selected from the group consisting of a drug suppressing vascularization, a drug promoting the growth of nerve cells, a steroid drug, a therapeutic drug for glaucoma, an anti-inflammatory drug, an antifungal drug, and an anticancer drug.

13. A sustained drug delivery system in which an implant is implanted in the body, wherein the implant is the drug slow-releasing implant according to claim 1.